|Goodman and Gilman's the pharmacological basis of therapeutics|
|Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase|
D Salonga, KD Danenberg, M Johnson, R Metzger, S Groshen, ...
Clinical Cancer Research 6 (4), 1322-1327, 2000
|Clinical pharmacology of 5-fluorouracil|
RB Diasio, BE Harris
Clinical pharmacokinetics 16 (4), 215-237, 1989
|Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile|
GD Heggie, JP Sommadossi, DS Cross, WJ Huster, RB Diasio
Cancer research 47 (8), 2203-2206, 1987
|Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity.|
RB Diasio, TL Beavers, JT Carpenter
The Journal of clinical investigation 81 (1), 47-51, 1988
|Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels …|
BE Harris, R Song, S Soong, RB Diasio
Cancer research 50 (1), 197-201, 1990
|Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks|
WE Dismukes, G Cloud, HA Gallis, TM Kerkering, G Medoff, PC Craven, ...
New England Journal of Medicine 317 (6), 334-341, 1987
|Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical …|
Z Lu, R Zhang, RB Diasio
Cancer research 53 (22), 5433-5438, 1993
|Quantitation of dihydropyrimidine dehydrogenase expression by real-time reverse transcription polymerase chain reaction|
MR Johnson, K Wang, JB Smith, MJ Heslin, RB Diasio
Analytical biochemistry 278 (2), 175-184, 2000
|A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor–negative breast cancer in the general population|
AC Antoniou, X Wang, ZS Fredericksen, L McGuffog, R Tarrell, ...
Nature genetics 42 (10), 885-892, 2010
|Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing|
KE Caudle, CF Thorn, TE Klein, JJ Swen, HL McLeod, RB Diasio, ...
Clinical Pharmacology & Therapeutics 94 (6), 640-645, 2013
|A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor–negative breast cancer|
CA Haiman, GK Chen, CM Vachon, F Canzian, A Dunning, RC Millikan, ...
Nature genetics 43 (12), 1210-1214, 2011
|The continuum of care: a paradigm for the management of metastatic colorectal cancer|
RM Goldberg, ML Rothenberg, E Van Cutsem, AB Benson III, CD Blanke, ...
The oncologist 12 (1), 38-50, 2007
|Method of down-regulating gene expression|
S Agrawal, RB Diasio, R Zhang
US Patent 5,591,721, 1997
|Severe 5‐fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome|
BE Harris, JT Carpenter, RB Diasio
Cancer 68 (3), 499-501, 1991
|Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil|
MR Johnson, A Hageboutros, K Wang, L High, JB Smith, RB Diasio
Clinical Cancer Research 5 (8), 2006-2011, 1999
|Histone Deacetylase Inhibitors|
X Ma, HH Ezzeldin, RB Diasio
Drugs 69 (14), 1911-1934, 2009
|Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis|
AM Stamm, RB Diasio, WE Dismukes, S Shadomy, GA Cloud, CA Bowles, ...
The American journal of medicine 83 (2), 236-242, 1987
|Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update|
U Amstutz, LM Henricks, SM Offer, J Barbarino, JHM Schellens, JJ Swen, ...
Clinical Pharmacology & Therapeutics 103 (2), 210-216, 2018
|Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency.|
CH Takimoto, ZH Lu, R Zhang, MD Liang, LV Larson, LR Cantilena, ...
Clinical cancer research 2 (3), 477-481, 1996